Recent Updates — CTRVP
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS) by paying $2 million in cash, issuing 25 million shares of common stock, and assuming a $1 million promissory note. The transaction includes an additional $135,000 payment to the seller. GLS is developing GV104 for opioid-induced respiratory depression and GV023 for inflammatory conditions. Concurrently, Hepion appointed Sireesh Appajosyula as Chief Executive Officer and Gary Stetz as Chief Financial Officer, effective October 9, 2026. The company operates in the biotechnology sector.
Hepion Pharmaceuticals, Inc. dismissed Grassi & Co., CPAs, P.C. as its independent registered public accounting firm and engaged Rosenberg Rich Baker Berman P.A. (RRBB) effective September 21, 2026. The prior auditor's reports on fiscal years ended December 31, 2025 and 2024 contained an explanatory paragraph noting substantial doubt regarding the company's ability to continue as a going concern due to significant operating losses and negative cash flows. There were no reportable events or disagreements with Grassi on accounting principles, financial statement disclosures, or auditing scope. Hepion Pharmaceuticals operates in the biotechnology industry, focusing on drug discovery and development.
On September 3, 2026, Hepion Pharmaceuticals entered into a convertible note purchase agreement with Gravitas Capital LP to issue a $500,000 secured convertible note. The note bears interest at 8% per annum, payable in kind, and matures on September 3, 2027. It is convertible at the option of Gravitas at a price of $0.04 per share, contingent upon stockholder approval to increase authorized common shares. Additionally, Hepion issued a warrant for 12,500,000 shares exercisable at $0.06 per share until September 3, 2031, also subject to the same stockholder approval condition. The note is secured by all of the company's assets under a separate security agreement. Hepion Pharmaceuticals operates in the biopharmaceutical industry.
On August 25, 2026, Hepion Pharmaceuticals entered into securities purchase agreements with accredited investors to sell and issue 8,000,000 shares of common stock and warrants to purchase an additional 8,000,000 shares in a private placement. The offering price was $0.05 per share, generating gross proceeds of $400,000. The accompanying warrants are exercisable at $0.06 per share for five years from issuance. This transaction was conducted under Section 4(a)(2) and Regulation D exemptions. Hepion Pharmaceuticals operates in the biotechnology industry, focusing on drug discovery and development.
On August 19, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. approved the appointment of James Liddy as a director, effective immediately. The filing confirms no arrangements or understandings existed between Mr. Liddy and other persons regarding his selection, nor are there reportable transactions under Regulation S-K Item 404(a). Hepion Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development of therapies for rare diseases.